What question did this study set out to answer?

To evaluate the predictive capability of the triglyceride glucose index and atherogenic index of plasma on rapid kidney function decline in cardiovascular-kidney-metabolic syndrome.

January 10, 2026European journal of medical research0 citationsOpen Access

Triglyceride glucose index and atherogenic index of plasma predict rapid kidney function decline in cardiovascular–kidney–metabolic syndrome: the first longitudinal evidence from CHARLS

XCXueqi Chen YWYifan Wang MDMengying Dong

Key Result

The triglyceride glucose index and atherogenic index of plasma are effective biomarkers for predicting rapid kidney function decline in cardiovascular–kidney–metabolic syndrome.

Key Points

To evaluate the predictive capability of the triglyceride glucose index and atherogenic index of plasma on rapid kidney function decline in cardiovascular-kidney-metabolic syndrome.
Longitudinal analysis of clinical data from the CHARLS cohort
Assessment of triglyceride glucose index and atherogenic index of plasma
Measurement of uric acid levels and their mediating effects
Both triglyceride glucose index and atherogenic index significantly predict rapid kidney function decline
Uric acid shows a significant mediating role in this relationship
Findings support the potential use of these biomarkers in clinical risk stratification for CKM syndrome

Structured PICO

Do elevated TyG index and AIP predict rapid kidney function decline in patients with cardiovascular-kidney-metabolic syndrome?

Population

2,763 participants aged ≥45 years with cardiovascular-kidney-metabolic (CKM) syndrome stages 1-4 and baseline eGFR ≥15 mL/min/1.73m2, median age 60.0, 44.1% male, from the China Health and Retirement Longitudinal Study (CHARLS).

Intervention

Elevated Triglyceride-glucose (TyG) index and atherogenic index of plasma (AIP), analyzed as continuous variables and by quartiles.

Comparator

Lowest quartile (Q1) of TyG index and AIP.

Outcome

Rapid kidney function decline (RKFD), defined as an annual decline in eGFR of at least 3 ml/min/1.73m2 during the follow-up period.surrogate

The TyG index and AIP are effective, independent biomarkers for stratifying the risk of rapid kidney function decline in patients with cardiovascular-kidney-metabolic syndrome.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Our findings demonstrate the utility of the TyG index and AIP as effective biomarkers for stratifying the risk of RKFD in the clinical management of CKM syndrome. Furthermore, uric acid plays a significant partial mediating role in this relationship.

Ask AI

Helpful

Bookmark

View Full Paper